Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.

Hong YM, Yoon KT, Hwang TH, Heo J, Woo HY, Cho M.

Eur J Gastroenterol Hepatol. 2019 Mar 28. doi: 10.1097/MEG.0000000000001405. [Epub ahead of print]

PMID:
30925530
2.

10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein.

Lee DH, Hasanuzzaman M, Kwon D, Choi HY, Kim SM, Kim DJ, Kang DJ, Hwang TH, Kim HH, Shin HJ, Shin JG, Oh S, Lee S, Kim SW.

Curr Pharm Des. 2018;24(46):5590-5597. doi: 10.2174/1381612825666190222155700.

PMID:
30799787
3.

Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus.

Cho E, Ryu EJ, Jiang F, Jeon UB, Cho M, Kim CH, Kim M, Kim ND, Hwang TH.

Drug Des Devel Ther. 2018 Aug 8;12:2467-2474. doi: 10.2147/DDDT.S171269. eCollection 2018.

4.
5.

Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.

Lee NH, Kim M, Oh SY, Kim SG, Kwon HC, Hwang TH.

Oncotarget. 2017 Jan 3;8(1):1213-1225. doi: 10.18632/oncotarget.13598.

6.

Seasonal Patterns of Asthma in Children and Adolescents Presenting at Emergency Departments in Korea.

Won YK, Hwang TH, Roh EJ, Chung EH.

Allergy Asthma Immunol Res. 2016 May;8(3):223-9. doi: 10.4168/aair.2016.8.3.223.

7.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS.

Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.

8.

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH.

Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.

PMID:
26072416
9.

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH.

Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Review.

PMID:
25900822
10.

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J.

Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Review.

11.

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ.

Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.

12.

First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

13.

A fully integrated sensor SoC with digital calibration hardware and wireless transceiver at 2.4 GHz.

Kim DS, Jang SJ, Hwang TH.

Sensors (Basel). 2013 May 21;13(5):6775-92. doi: 10.3390/s130506775.

14.

Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

15.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.

Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.

16.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.

17.

Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Park SN, Noh KT, Jeong YI, Jung ID, Kang HK, Cha GS, Lee SJ, Seo JK, Kang DH, Hwang TH, Lee EK, Kwon B, Park YM.

Exp Mol Med. 2013 Feb 8;45:e8. doi: 10.1038/emm.2013.14.

18.

An on-time power-aware scheduling scheme for medical sensor SoC-based WBAN systems.

Hwang TH, Kim DS, Kim JG.

Sensors (Basel). 2012 Dec 27;13(1):375-92. doi: 10.3390/s130100375.

19.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

20.

Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines.

Lee HJ, Rho J, Gui SR, Kim MK, Lee YK, Lee YS, Kim JE, Cho E, Cho M, Hwang TH.

Korean J Hepatol. 2011 Sep;17(3):213-9. doi: 10.3350/kjhep.2011.17.3.213.

Supplemental Content

Loading ...
Support Center